Genomics-guided precision medicine for metastatic breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

CATCH is an observational study that aims to implement genomics-guided precision medicine for patients with metastatic breast cancer. It involves collecting tumor and blood samples from patients at the time of diagnosis or disease progression to conduct genomic and transcriptomic profiling. This profiling helps identify biomarkers and potential drug targets, guiding personalized therapeutic interventions. The study seeks to integrate these precision oncology workflows into clinical practice to improve treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female and male breast cancer patients ≥ 18 or if the legal guardian has agreed to the respective informed consent form (ICF)
* Patients with advanced or metastatic breast cancer (irrespective of clinical parameters such as TNM, subgroups, therapy lines)
* Patients, who agreed to and were able to sign the informed consent form.

Exclusion Criteria:

* Early breast cancer
* Inability to take a tissue bioptic sample due to reasons such as physical location of the lesion or health of the patient
* Any physical or mental handicap or severe comorbidities that would hamper the adequate cooperation with the patient.

Where it's running

• University Hospital Augsburg
  Augsburg, Germany Recruiting
• Charité
  Berlin, Germany Recruiting
• University Hospital Köln
  Cologne, Germany Recruiting
• Medical Faculty and University Hospital Carl Gustav Carus
  Dresden, Germany Recruiting
• University Hospital Erlangen
  Erlangen, Germany Recruiting
• University Hospital Essen
  Essen, Germany Recruiting

Study contacts

• Principal investigator: Andreas Schneeweiss, MD — National Center for Tumor Diseases, Heidelberg
• Study coordinator: Andreas Schneeweiss, MD
• Email: Andreas.Schneeweiss@med.uni-heidelberg.de
• Phone: 0049-6221-5636051

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Personalized treatment after endocrine therapy failure in metastatic breast cancer

  The study tests whether using a patient’s fresh tumor sample to try different drugs outside the body can help pick the next therapy for hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07895160

• SSGJ-612 plus a HER2-targeted ADC in HR-positive, HER2-low metastatic breast cancer

  This phase II study tests whether adding SSGJ-612 to a HER2-targeted antibody-drug conjugate helps people with HR-positive, HER2-low or ultralow metastatic breast cancer.

  Recruiting Phase 2 Shenyang Sunshine Pharmaceutical Co., LTD. · Guangzhou, Guangdong · NCT07757230

• SMP-656 in HER2-positive advanced breast cancer after ADC therapy

  This trial tests whether SMP-656 given by IV every 3 weeks can help people with HER2-positive locally advanced or metastatic breast cancer who progressed after a HER2-targeted antibody-drug conjugate.

  Recruiting Phase 2 Chengdu SciMount Pharmatech Co., Ltd. · Hefei, Anhui and 14 other locations · NCT07726342

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer

  This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.

  Recruiting at 5 sites Phase 3 Daiichi Sankyo · Columbia, Maryland and 4 other locations · NCT07683754

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.